Catalent Launches New Oral Developability Assessment and Manufacturing Solution to Advance Targeted Protein Degrader Programs
March 30, 2023
March 30, 2023
SOMERSET, New Jersey, March 30 -- Catalent Inc., a pharma, biotech and consumer health company, issued the following news on March 29, 2023:
Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the launch of the ProteoSuiteSM Oral suite, which allows the rational selection of orally developable targeted protein degrader (TPD) candidates and their advancement into clinical trials. These emerging therapeutic modalitie . . .
Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the launch of the ProteoSuiteSM Oral suite, which allows the rational selection of orally developable targeted protein degrader (TPD) candidates and their advancement into clinical trials. These emerging therapeutic modalitie . . .